Women Directors International 2006 Report:
"Women Board Directors of the
and Pharmaceutical Companies"
The good news:
the largest global healthcare and pharmaceutical
companies appoint women to their boards at a slightly higher rate than
Fortune Global 200, the 200 largest companies in the world – 11.5%
The good news:
U.S.-based healthcare and pharmaceutical companies have a
better percentage of women directors at 16.4% than the national
average of 14.7% among the Fortune 500. In an
industry-to-industry comparison, the healthcare companies also outpace
the largest U.S. banks in terms of women board directors – 16.4% vs.
The bad news:
only 65.2% of the Financial Times 500 healthcare and
pharmaceutical companies have at least one woman on their boards of
directors. This leaves 35.8% of companies without a single
female director, including GlaxoSmithKline, the third largest in the
companies lag behind healthcare companies in including women on their
boards – 9.6% to 14.3%.
Wellpoint, a health
benefits company, ranks first in CWDI’s Top Five list of healthcare
and pharmaceutical companies with the highest percentage of women
directors at 31.3% or 5 out of 16 directors.
and Johnson & Johnson all tie for second place with 30.8% of their
board directors being female.
The largest American
pharmaceutical and healthcare companies outpace their European
counterparts in appointing women to corporate boards – 16.4% to 9.9%.
None of the 22
Japanese healthcare and pharmaceutical companies included in the
Financial Times 500 listings had a single woman on their boards.
The percentage of
women executive officers in healthcare and pharmaceutical companies
(9.8%) is lower than the percentage of women directors serving on the
boards of those companies (11.5%), creating a limited pool from which
to draw future directors or CEOs.
Almost half of the
companies covered in this report -- 44 out of 92 – have no senior
women executive officers in their executive management team.